Related articles:
Catecholaminergic polymorphic ventricular tachycardia
Antiarrhythmic agent
AV nodal reentrant tachycardia
Brugada syndrome
Propafenone
Amiodarone
Atrial fibrillation
CYP2D6
Key terms:
heart
increased
ventricular
dose
treatment
effect
levels
arrhythmias
individuals
tachycardia
toxicity
agents
should
elimination
sodium
failure
cardiac
disease
decrease
risk
plasma
cytochrome
heart disease
signs
heart rate
myocardial
atrial
antiarrhythmic agent
ventricular tachycardia
heart failure
steady state
liver
prolongation
patients
adjusted
achieved
occur
rapid
conduction
administration
may increase
paroxysmal
supraventricular tachycardia
electrical
metabolism
therefore
ecg
interactions
blocking
atrial fibrillation
ejection fraction
renal
inhibits
starting
contractility
Search external links cited by footnotes on Wikipedia page Flecainide:
|
|